A Sum Score to Define Therapy-Refractory Myasthenia Gravis: A German Consensus

Background and purpose: In 2017, eculizumab has been approved for treatment-refractory generalised myasthenia gravis (TRgMG). The German Myasthenia Foundation has published a consensus statement on the use of eculizumab, with a recent update. However, a treatment-refractory state is still ill-define...

Full description

Bibliographic Details

Published in:	Journal of Central Nervous System Disease
Main Authors:	Michael Schroeter, Benjamin Berger, Franz Blaes, Tim Hagenacker, Sebastian Jander, Julia Kaiser, Petra Kalischewski, De-Hyung Lee, Tobias Ruck, Ulrike Schara, Peter Urban, Andreas Meisel
Format:	Article
Language:	English
Published:	SAGE Publishing 2021-02-01
Online Access:	https://doi.org/10.1177/1179573521989151